NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis $1.75 -0.01 (-0.47%) Closing price 05/29/2025 03:58 PM EasternExtended Trading$1.72 -0.02 (-1.21%) As of 05/29/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CalciMedica Stock (NASDAQ:CALC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CalciMedica alerts:Sign Up Key Stats Today's Range$1.69▼$1.7650-Day Range$1.48▼$2.0752-Week Range$1.43▼$5.99Volume24,011 shsAverage Volume45,113 shsMarket Capitalization$24.40 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company OverviewCalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Read More… CalciMedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCALC MarketRank™: CalciMedica scored higher than 41% of companies evaluated by MarketBeat, and ranked 702nd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalciMedica has only been the subject of 1 research reports in the past 90 days.Read more about CalciMedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalciMedica has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CalciMedica's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.05% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently increased by 87.39%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.05% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently increased by 87.39%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.44 News SentimentCalciMedica has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CalciMedica this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CALC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have not sold or bought any company stock.Percentage Held by Insiders41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CalciMedica's insider trading history. Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address CALC Stock News HeadlinesCalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesMay 15, 2025 | finanznachrichten.deCalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesMay 14, 2025 | prnewswire.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.May 30, 2025 | Brownstone Research (Ad)CalciMedica Announces Presentations at Upcoming Medical MeetingsApril 17, 2025 | prnewswire.comCalciMedica to Participate in the Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | prnewswire.comCalciMedica Inc. Common StockMarch 27, 2025 | 247wallst.comCalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate UpdatesMarch 27, 2025 | prnewswire.comCalciMedica Shares Drop After Securing New Credit FacilityMarch 5, 2025 | marketwatch.comSee More Headlines CALC Stock Analysis - Frequently Asked Questions How have CALC shares performed this year? CalciMedica's stock was trading at $3.54 at the start of the year. Since then, CALC stock has decreased by 50.7% and is now trading at $1.7462. View the best growth stocks for 2025 here. How were CalciMedica's earnings last quarter? CalciMedica, Inc. (NASDAQ:CALC) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. Who are CalciMedica's major shareholders? Top institutional shareholders of CalciMedica include Stonepine Capital Management LLC (2.63%), Wealthedge Investment Advisors LLC (0.78%), Cambridge Investment Research Advisors Inc. (0.17%) and 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts and A Rachel Leheny. View institutional ownership trends. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CalciMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM). Company Calendar Last Earnings5/14/2025Today5/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALC CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$20.00 Low Stock Price Target$16.00 Potential Upside/Downside+930.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-164.24% Return on Assets-103.53% Debt Debt-to-Equity RatioN/A Current Ratio4.15 Quick Ratio4.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.23Miscellaneous Outstanding Shares13,972,000Free Float7,880,000Market Cap$24.40 million OptionableNo Data Beta1.24 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:CALC) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.